Mantle cell lymphoma: Are current therapies changing the course of disease?

Geisler, Christian H.

doi:10.1007/s11912-009-0050-2

Cited by 3 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, an objective response was achieved in 45% of patients receiving bortezomib, with median progression-free survival of only 6 months 6. Fifty-three percent of patients responded well to lenalidomide, with a median duration of response of 13.7 months and median progression-free survival of 5.6 months 7,8…”

Section: Mantle Cell Lymphomamentioning

confidence: 99%

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

Galimberti

Petrini²

2010

CMAR

View full text Add to dashboard Cite

Patients with mantle cell lymphoma (MCL) have a poor prognosis; consequently, new therapeutic approaches, such as rapamycin and its derivates, mammalian target of rapamycin (mTOR) inhibitors, are warranted. Temsirolimus (also known as CCI-779), a dihydroester of rapamycin, in MCL cell lines inhibited mTOR, downregulated p21 and v-Raf, and induced autophagy. The first clinical trial in MCL patients was performed using 250 mg of temsirolimus weekly for 6–12 cycles. The overall response rate was 38%; the median time to progression was 6.5 months, median overall survival was 12 months, and the median duration of response was 6.9 months. At lower dose (25 mg/week), the overall response rate was 41%, median overall survival was 14 months, and time to progression was 6 months. In another trial, 162 patients were randomly assigned to receive temsirolimus at 2 different doses (175 mg/week for 3 weeks, then 75 mg or 25 mg/week) or a treatment chosen by the investigator among the most frequently adopted single agents for treatment of relapsed MCL. Patients treated with 175/75 mg of temsirolimus had significantly higher response rates and longer progression-free survival than those treated with investigator’s choice therapy. These data support the use of mTOR inhibitors for the treatment of MCL, probably in combination with other agents, such as antiangiogenic drugs or histone acetylase inhibitors.

show abstract

Section: Mantle Cell Lymphomamentioning

confidence: 99%

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

Galimberti

Petrini²

2010

CMAR

View full text Add to dashboard Cite

show abstract

“…6 Fiftythree percent of patients responded well to lenalidomide, with a median duration of response of 13.7 months and median progression-free survival of 5.6 months. 7,8…”

Section: Mantle Cell Lymphomamentioning

confidence: 99%

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

Galimberti¹

2010

CMR

View full text Add to dashboard Cite

Patients with mantle cell lymphoma (MCL) have a poor prognosis; consequently, new therapeutic approaches, such as rapamycin and its derivates, mammalian target of rapamycin (mTOR) inhibitors, are warranted. Temsirolimus (also known as CCI-779), a dihydroester of rapamycin, in MCL cell lines inhibited mTOR, downregulated p21 and v-Raf, and induced autophagy.The first clinical trial in MCL patients was performed using 250 mg of temsirolimus weekly for 6-12 cycles. The overall response rate was 38%; the median time to progression was 6.5 months, median overall survival was 12 months, and the median duration of response was 6.9 months. At lower dose (25 mg/week), the overall response rate was 41%, median overall survival was 14 months, and time to progression was 6 months. In another trial, 162 patients were randomly assigned to receive temsirolimus at 2 different doses (175 mg/week for 3 weeks, then 75 mg or 25 mg/week) or a treatment chosen by the investigator among the most frequently adopted single agents for treatment of relapsed MCL. Patients treated with 175/75 mg of temsirolimus had significantly higher response rates and longer progression-free survival than those treated with investigator's choice therapy. These data support the use of mTOR inhibitors for the treatment of MCL, probably in combination with other agents, such as antiangiogenic drugs or histone acetylase inhibitors.

show abstract

O transplante de células-tronco hematopoéticas no tratamento dos linfomas não Hodgkin

Baldissera¹,

Bigni²,

Neto³

et al. 2010

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

No final da década de 70, ocorreu o primeiro relato de sucesso com a utilização de quimioterapia de alta dose, seguida de transplante de células-tronco hematopoéticas autólogo (TCTH auto), em pacientes com linfoma não Hodgkin (LNH). Desde então, o TCTH autólogo vem se constituindo em um importante instrumento na estratégia de tratamento dos LNH. Inúmeros estudos, em vários subtipos de linfomas, têm consolidado o papel do TCTH autólogo, principalmente como resgate em recidivas de doença. O melhor momento para a incorporação desta estratégia depende do subtipo do linfoma, do status de doença previamente ao transplante (sensível ou resistente) e de fatores clínico-biológicos associados à doença. Em recidiva sensível de linfoma difuso de grandes células, o TCTH autólogo é a terapia de escolha. Nestes pacientes, o transplante promove taxas de resposta completa em até 50% dos casos, comparado a aproximadamente 15%, quando esse resgate é realizado com protocolos quimioterápicos convencionais. O seu papel como parte da terapia de indução de remissão não está totalmente estabelecido. Em linfomas indolentes, principalmente folicular, é a terapia de escolha nas recidivas sensíveis à quimioterapia de resgate. Em linfomas de células do manto, o TCTH autólogo tem se incorporado à terapia de primeira linha, como consolidação de remissão. As indicações de TCTH alogênico em LNH têm se limitado aos casos de refratariedade ao tratamento convencional e recidiva pós-transplante autólogo, em pacientes jovens e sem comorbidades, em decorrência da alta toxicidade associada à utilização de regimes de condicionamento mieloablativos. A utilização de regimes de condicionamento de intensidade reduzida tem reduzido a toxicidade e ampliado o seu uso nos LNH recidivados ou refratários.

show abstract

Mantle cell lymphoma: Are current therapies changing the course of disease?

Cited by 3 publications

References 50 publications

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma

O transplante de células-tronco hematopoéticas no tratamento dos linfomas não Hodgkin

Contact Info

Product

Resources

About